Assessing Plasmin Generation in Health and Disease

• Published in: International journal of molecular sciences Vol. 22; no. 5; p. 2758
• Main Authors: Miszta, Adam, Huskens, Dana, Donkervoort, Demy, Roberts, Molly J M, Wolberg, Alisa S, de Laat, Bas
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 09.03.2021; MDPI AG
• Subjects: Animals; Antifibrinolytic Agents - blood; Blood Chemical Analysis - methods; Disease; Fibrin - analysis; Fibrin - chemistry; Fibrinolysin - analysis; Fibrinolysin - metabolism; fibrinolysis; Fibrinolytic Agents - blood; Humans; plasmin; plasmin generation; Plasminogen - analysis; Plasminogen - chemistry; Plasminogen - metabolism; Review; fibrinolysis; plasmin; plasmin generation
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22052758

Fibrinolysis is an important process in hemostasis responsible for dissolving the clot during wound healing. Plasmin is a central enzyme in this process via its capacity to cleave fibrin. The kinetics of plasmin generation (PG) and inhibition during fibrinolysis have been poorly understood until the recent development of assays to quantify these metrics. The assessment of plasmin kinetics allows for the identification of fibrinolytic dysfunction and better understanding of the relationships between abnormal fibrin dissolution and disease pathogenesis. Additionally, direct measurement of the inhibition of PG by antifibrinolytic medications, such as tranexamic acid, can be a useful tool to assess the risks and effectiveness of antifibrinolytic therapy in hemorrhagic diseases. This review provides an overview of available PG assays to directly measure the kinetics of plasmin formation and inhibition in human and mouse plasmas and focuses on their applications in defining the role of plasmin in diseases, including angioedema, hemophilia, rare bleeding disorders, COVID-19, or diet-induced obesity. Moreover, this review introduces the PG assay as a promising clinical and research method to monitor antifibrinolytic medications and screen for genetic or acquired fibrinolytic disorders.